Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

4 results
Display

Real-Life Effectiveness and Tolerability of Perampanel in Pediatric Patients Aged 4 Years or Older with Epilepsy: A Korean National Multicenter Study

Hwang SK, Lee YJ, Nam SO, Kim WS, Kim JS, Kim SJ, Lee YJ, Kwon S

BACKGROUND AND PURPOSE: The US Food and Drug Administration approval for perampanel has only recently been expanded to patients as young as 4 years, and so there have been few...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Tolerability of Low-Dose Perampanel in Patients with Childhood-Onset Intractable Epilepsy

Park H, Ahn H, Jang HN, Kim HJ, Yum MS, Ko TS

PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of perampanel as adjunctive therapy in childhood-onset refractory epilepsy. METHODS: We retrospectively reviewed the medical records of 110...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Tolerability of Low-Dose Perampanel in Patients with Childhood-Onset Intractable Epilepsy

Park H, Ahn H, Jang HN, Kim HJ, Yum MS, Ko TS

PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of perampanel as adjunctive therapy in childhood-onset refractory epilepsy. METHODS: We retrospectively reviewed the medical records of 110...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy

Youn SE, Kim SH, Ko A, Lee SH, Lee YM, Kang HC, Lee JS, Kim HD

BACKGROUND AND PURPOSE: Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr